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Abstract : The aim of the present study was to evaluate the effects of anodized implants coated with Escherichia
coli-derived recombinant human bone morphogenetic protein-2 (ErhBMP-2) on osseointegration using stability
tests and histometric analysis. Nine adult New Zealand white rabbits (4.5-5 kg) were used in the study. Thirty-six
implants (L, 5.0 mm; D, 4.0 mm) were divided into 2 groups: anodized implants (control group) and ErhBMP-
2(1.5 mg/ml concentration, 18 µg: Cowellmedi Co, Busan, Korea) coated anodized implant (experimental group).
In each rabbit, 4 implants were placed in the tibia on both sides. The control and experimental implants were ran-
domly placed in either left or right tibia. The rabbits were sacrificed at the end of the healing period (2, 4 and 12
weeks after operation). The stability of implants was evaluated by resonance frequency analysis. To obtain histomet-
ric results, bone to implant contact (BIC) and intra-thread bone density (ITBD) were measured with a light micro-
scope. The ISQ value was significantly greater in the experimental group than in the control group at 12 weeks
(P<0.05). ITBD increased over time in the experimental group (P<0.05). Post hoc comparison test analysis showed
that a statistically significant change could be found between 2 and 4 weeks in the interaction between the ITBD
change by time lapse and an ErhBMP-2 application condition (P=0.033). In this study, a greater degree of ossointe-
gration was observed in the experimental group. ErhBMP-2 coated anodized implants could be used particularly in
cases where bone quality is poor or bone volume is insufficient. 
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1. Introduction
BMP, a protein from a subgroup of the transforming growth
factor â family, accelerates ossification by controlling the
essential factors of the bone induction cascade, resulting in the
proliferation of osteoblasts from mesenchymal stem cells and the
biosynthesis of bone matrix.1-6 Because BMP-2 possesses high
osteoinductive potential,7 it has been considered to be an
interesting candidate growth factor to coat titanium implants.
While BMP-2 has been more commonly used, BMP-4 is
currently considered as a candidate growth factor that might
improve the remodeling process at the bone-implant interface.8
BMP-2 has proved to be beneficial, thus it can be used for
various medical treatments.9 It has been reported that recombinant
human BMP-2 (rhBMP-2), which is extracted by the gene
recombination technique, can execute an osteoinductive effect
when coated on the surface of implants.10-12 In particular, Hall et
al10 concluded that an osteoinductive effect, including bone contact
with the implant surface, is in the advantage of titanium porous
oxide surface (anodized surface) in yielding the most bone at a low
discriminating rhBMP-2 dose.
Recombinant human BMPs are currently produced by BMP
gene-transfected mammalian cell (CHO) cultures13,14 and
rhBMP-2 and BMP-7 (rhBMP-7/ osteogenic protein-1 [OP-1])
are commercially available for the treatment of bony defects.15,16
One of the problems associated with clinical application of CHO-
cell-derived rhBMP-2 (CrhBMP-2) is its high cost due to a high
dose requirement. One possible way of solving this problem is to
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produce monomer rhBMPs in BMP-gene transfected
Escherichia coli (E. coli) with a high efficiency of production and
low cost. Besso et al17 examined the bone-inducing ability of an E.
coli-derived rhBMP-2 (ErhBMP-2) variant with an N-terminal
sequence and compared it with CrhBMP-2. Quantitative analysis
indicated that the activity of ErhBMP-2 is similar to that of
CrhBMP-2. However, it is unclear whether the characteristics of
ErhBMP-2 are appropriate for clinical applica-tion. In particular,
the outcome and effect of ErhBMP-2 coating in osseointegration
have not yet been determined. Therefore, the present study was
conducted to evaluate the effect of ErhBMP-2 on the
osseointegration of anodized implants using stability tests and
histometric analysis. 
2. Materials and Methods
2.1 Fabrication of Implant
Thirty-six implants (5.0 mm in length, 4.0 mm in diameter;
Cowellmedi Co, Busan, Korea) were fabricated (Table 1). All
thread-type implants were made of pure titanium, and they were
designed to have microthreads on the upper part, and broader
threads on the lower part (Fig 1). The implant surface was treated
by the anodizing method (Cowellmedi Co), and half of the
implant (18 implants) was processed by coating with ErhBMP-2
(Cowellmedi Co). The bioactivity of ErhBMP-2 (Cowellmedi
Co., Pusan Korea) used in this study was validated in the recent
study regarding the possibility of vertical bone growth using
ErhBMP-2 coated implant.18 To coat with ErhBMP-2, they were
immersed 3 times in protein solution (1.5 mg/ml concentration)
up to the microthreads of the implants and were freeze dried
under sterile conditions (Freeze drying at -40oC, followed by
vacuum drying at maximum 20oC). The total dose of ErhBMP-2
coated onto implant was 18 µg in each implant.
2.2 Experimental Animals
This study was carried out with the approval from the Ethics
Committee on Animal Experimentation of Korea University
(UIACUC-20091203-1). Nine adult New Zealand white
rabbits (males, 5; females, 4), weighing 4.5-5 kg, were used for
this study and given 2 weeks to acclimatize. The rabbits were
given conventional laboratory diet during the observation
period. During surgery, Zoletil50® (Vibac, Carros, France) at an
intramuscular dose of 0.16 ml/kg was used for general
anesthesia and approximately 1 ml of lidocaine (Yu-Han Co,
Gunpo, Korea) with epinephrine 1:100,000 was infiltrated into
the mucosa of the surgical site. 
2.3 Surgical Procedure
2.3.1 Implant Surgery
All animal experiments were performed in an absolute sterile
animal experimentation room. The rabbits were laid down on their
back with the limbs immobilized, and they were disinfected before
a semilunar incision was made in the part of the articulating area of
the limb to separate skin, fascia and periosteum. 
For the placement of implants at the same location on both
sides, the exposed bone was marked at the implant placement
sites using a ruler. A guide drill in an implant surgical set
(Cowellmedi Co) was used to drill cortical bone, and then a 2-mm
first drill, a 3-mm pilot drill and a 3.2-mm final drill were used
before countersinking. Four implants were placed in the tibia on
both sides. However, since ErhBMP-2 released in ErhBMP-2-
coated implants can modify the surrounding environment, the
control and experimental implants were placed in either the left
or right side. Implant stability quotient (ISQ) values were
measured for each implant to evaluate stability at the time of
implant placement. To suture periosteum and skin separately, 4-0
nylon (Mersilk, Ethicon Co, Livingston, U.K.) was used.
Table 1. Classification of the experimental implants
Time(Weeks)
2 wk 4 wk 12 wk Total
Control Group 6 6 6 18
Experimental Group 6 6 6 18
Total 12 12 12 36
Control Group: Anodized implant
Experimental Group: Anodized implant coated with ErhBMP-2
Figure 1. Diagram of implant. The implant was designed to have
microthreads on the upper part and broader threads on the lower
part (5.0 mm in length, 4.0 mm in diameter).
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2.3.2 Postoperative Care and Sacrifice
The rabbits were administered gentamicin intramuscularly
(4 ml/kg; Kukje Pharmacy, Sungnam, Korea) immediately and
24 hours after surgery. Sutures were removed 1 week after the
placement of implants. The rabbits were given a soft diet for 2
weeks after surgery, followed by a conventional regular diet.
The experimental rabbits were divided into 3 groups based on
the time of sacrifice (2, 4 and 12 weeks after operation).
2.4 Measurement of Various Parameters
2.4.1 Assessment of Implant Stability
Implants placed in the tibia were measured for ISQ by Osstell
Mentor (Integration Diagnostic Ltd, Göteborg, Sweden) during
surgery, and 2, 4 and 12 weeks after surgery. ISQ values were
recorded 5 times for each implant, and 3 values excluding the
minimum and maximum values were calculated for the mean
and standard deviation for the evaluation of changes in implant
stability.
2.4.2 Histometric Analysis 
At the end of each time point, the animals were sacrificed, and
specimens including the implants were collected from the tibia
after the measurement of implant stability using Ostell Mentor.
The specimens were fixed in neutral buffered formalin (Sigma
Aldrich, St Louis, MO, USA) for 2 weeks and dehydrated in
ascending concentrations of ethanol 70%, 80%, 90% and 100%.
The dehydrated specimens were embedded in Technovit 7200
resin (Heraeus KULZER, South Bend, IN, USA). The blocks of
the polymerized specimens were sectioned longitudinally from
the center of each implant by an EXAKT diamond cutter
(KULZER EXAKT 300, EXAKT, Norderstedt, Germany). The
30-µm final slides were prepared from the initial 400-µm slides
by grinding the sections with an EXAKT grinding machine
(KULZER EXAKT 400CS, EXAKT). The specimens were
stained with Goldner Trichrome. The images were captured
using a computer connected light microscope (Olympus BX,
Tokyo, Japan) attached to a CCD camera (Polaroid DMC2
digital Microscope Camera (Polaroid Corporation, Cambridge,
MA, USA)). All measurements were made using SPOT
Software V4.0 (Diagnostic Instrument, Inc., Sterling Heights,
MI, USA). The percentage of BIC was measured, and the ratio of
the area of bone formation on intra-threads of the implant to overall
threads was calculated for the measurement of ITBD (Fig 2). The
bone superior to the most apical thread was not included due to
difficulty in objectification. Overall specimen images were
captured at a magnification of X2.5. A magnification of X40 was
used for histometric analysis, and a 100X magnifica-tion lens for
a precise assessment of BIC. The criteria for histometric analysis
included images that were captured at a magnification of 40X. 
2.5 Statistical Analysis 
The mean and SD of the ISQ values, BIC and ITBD in the
histologic specimens were calculated for each group. The
statistical analysis for ISQ values was performed using the
Shapiro-Wilk method for normality test. Comparisons between
the experimental and control groups were made in the same
week using the Mann-Whitney U test. Analyses at periodic
time points were performed for the same group using the
Freidman test. Statistical analyses for BIC and ITBD were
performed using ANOVA(SPSS Inc, Chicago, IL, USA). Post
hoc comparison test analysis was used for finding the interac-
tion between the bone density change by a time lapse and an
ErhBMP-2 application condition. Statistical significance was
established at the 95% confidence level.
3. Results
3.1  ISQ Value
The overall ISQ value was higher in the control group than in
the experimental group immediately after surgery, but the
difference was not statistically significant. In the control group,
the ISQ value was relatively high at 2 weeks, but gradually
decreased at 4 and 12 weeks. However, in the experimental
group, the ISQ value was relatively low at 2 weeks but gradually
Figure 2. Measurement of intra-thread bone density. The ratio of the
area of bone formation on intra-threads of implant to overall threads
was calculated for the measurement of bone density (X 40).
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increased at 4 and 12 weeks (Table 2). The difference between
the 2 groups was statistically significant at 2 and 12 weeks
(P<0.05) (Fig 3). The Friedman test, which is used to assess
statistical significance at different time points in the same
group, revealed that the experimental group showed an increase
in the ISQ value with time (P<0.05).
3.2  Histometric Analysis 
The experimental group showed increased BIC at 2, 4 and 12
weeks after surgery. In the control group, BIC increased up to 4
weeks and decreased at 12 weeks. Although there was no
statistical significance between the 2 groups, the experimental
group showed a larger BIC at 12 weeks (Table 3). Considering
ITBD, the experimental group demonstrated a continuous
increase, while the control group showed a slight decrease (Figs
4 and Table 3). We used repeated-measures ANOVA for
statistical analysis. The Mauchly test indicated that the assump-
tion of sphericity had not been violated (χ2 = 2.820, P>0.05).
The results of the multivariate tests in the process of repeated-
measures ANOVA showed that the ITBD score by time lapse
was not significantly affected by the ErhBMP-2 application
(P>0.05). The interaction between ITBD score by time lapse
and ErhBMP-2 application was statistically significant
(P=0.044). Post hoc comparison analysis showed that a
statistically significant change could be found from 2 to 4
weeks between ITBD score by a time lapse and ErhBMP-2
application condition (P=0.033).
4. Discussion
BMPs were identified as osteoinductive proteins more than
40 years ago.19 Since the BMP gene was cloned, studies and
clinical applications of BMP have been widely conducted. A
problem associated with the clinical use of BMPs is their high
cost of production, since they are originally derived from
Table 2. Implant stability quotient (ISQ) values (mean ± SD).
Time (Weeks)
0 2 4 12
Control group 55.67±13.94 60.50±6.83 55.17±13.36 53.00±11.37
Experimental group 56.33±16.77 44.17±13.36 61.17±7.96 72.17±4.12
P-value 0.87 0.03 0.42 0.002
Figure 3. Implant stability quotient (ISQ) (mean±SD) A higher
ISQ value was recorded in the control group immediately after
surgery although the difference was not statistically significant.
In the control group, the ISQ value was slightly high at 2 weeks,
while the values decreased gradually at 4 and 12 weeks. In the
experimental group, the ISQ value was relatively low at 2 weeks
than immediately after surgery but gradually increased at 4 and
12 weeks. The difference between the 2 groups was statistically
significant at 2 and 12 weeks (P<0.05).
Table 3. Histometric parameters for osseointegration (means±SD of BIC and bone density).
Bone to implant contact (%) Intra-thread bone density (%)
Control Experimental Control Experimental
Week 2 21.62±10.16 23.51±16.27 67.52±8.97 44.77±15.09
Week 4 30.61±31.33 29.13±14.51 59.26±25.03 77.20±9.93
Week 12 23.82±9.79 34.63±15.17 58.66±29.63 70.20±7.32
The mean percentage of Bont to implant contact(BIC) and intra-thread bone density (ITBD) in individual groups. The overall BIC showed
no significant differences at 2 and 4 weeks between the 2 groups, but a higher BIC was observed in the experimental group at 12 weeks.
ITBD was significantly less in the experimental (ErhBMP-2) group at 2 weeks, but it showed a relatively great bone volume after 4 and
12 weeks, whereas the control group showed a decreased bone volume at 4 and 12 weeks. There was a statistical significance in the
interaction between study conditions (ErhBMP-2 and control groups) and periods (2,4 and 12 weeks)
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mammalian CHO cells.20 To solve this problem, Sebald et al.21,22
devised a novel method to produce rhBMP-2 derived from E.
coli and convert BMP monomers to biologically active dimers
(ErhBMP-2). ErhBMP-2 has an osteoinductive activity which
is similar to CHO-derived rhBMP-2 both in vivo and in vitro.23
However, these reports included only results for ErhBMP-2-
induced ectopic bone formation. The aim of our study was to
determine whether anodized implant coated with ErhBMP-2
could achieve better osseointegration than non-coated implant
in a rabbit tibia model. In this study, the total dose of ErhBMP-
2 coated and the concentration of ErhBMP-2 were 18 µg and
1.5 mg/ml in each implant respectively. These values were
referenced by previous studies conducted on the effectiveness
of implant coated with CHO cell derived rhBMP-2 on
osseointergration and vertical bone gain.11-12 Bone growth was
observed around the cervical area of ErhBMP-2 coated
implants when animals were sacrificed. It may be possibly due
to the peel-off and accumulation of ErhBMP-2 at the bone crest
while driving the implant into the bone drill hole for implant
installation. As the exact peel-off dose could not be measured,
further studies are needed to find out peel-off amount and
accumulating area. 
There were some limitations in this study. First, we used a
rabbit tibia model. For clinical application, studies must be
performed in much larger animals such as sheep or non-human
primates since the efficacy of cytokines and BMPs vary in
different species. In addition, bone quality in a rabbit tibia model
may differ depending on the site of implant placement. In this
study, differences in the initial stability were noted in the same
test subject depending on the site of implant placement. Second,
the sample size in each group was not sufficient to yield
substantial results, and the study is likely underpowered. 
Despite the limitations in this study with rabbits, the
experimental group showed a greater implant stability that was
statistically significant especially at 12 weeks. The findings of
this study are in accordance with other studies using rhBMP-2-
coated implants.3-5 The experimental group showed reduced
implant stability at 2 weeks, but the stability increased at 4 and
12 weeks. In the experimental group, the reduced implant
stability at 2 weeks may be attributed to rhBMP-2 facilitating
Figure 4. Light microphotographs (×¹12.5). Control group (A, 2 weeks; B, 4 weeks; C, 12 weeks), Experimental group (D, 2 weeks; E, 4
weeks; F, 12 weeks). Implants were inserted in the tibia of the rabbit that had a poor bone quality. The experimental group demonstrated
an increase in ITBD. However, there was no statistically significant difference in BIC at a magnification of X40.
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the proliferation of osteoclasts during the early stage of bone
healing, while at 4 and 12 weeks, the increased implant stability
may be due to the overall promotion of bone healing. Previous
studies have demonstrated that besides the promotion of bone
formation, BMPs stimulate recruitment, proliferation and
differentiation of osteoclasts.7,24 Hence, they may promote the
resorption of newly formed bone almost as soon as it has been
laid down onto a titanium implant surface.24 As compared to the
existing non-ErhBMP-2-coated implants, the ErhBMP-2
coated implants may not be ideal for immediate loading, but
they may be more suitable for delayed loading (12 weeks). 
The implants were stabilized at the initial time of implant
placement by compressing cortical bone. It may be speculated
that the decrease in implant stability at 2, 4 and 12 weeks was
caused by the remodeling of cortical bone by compression. The
tibias of the rabbits are composed of thin cortical bone and low
cancellous bone that are not optimal for anodized implant
osseointegration. Based on this result, osseoingetration of the
ErhBMP-2 coated implants could be achieved even at sites of
poor bone quality.
Histometric evaluation revealed a significant difference in
ITBD in the experimental group. ISQ values at 2 and 12 weeks
were in agreement with ITBD values, while ISQ value at 4 weeks
failed to show a significant correlation with bone formation. The
bone was not sufficiently mature at 4 weeks to increase the ISQ
value, despite the formation of new bone promoted by ErhBMP-
2. The overall BIC showed no significant differences at 2 and 4
weeks between the 2 groups, but a higher BIC was observed in
the experimental group at 12 weeks. A statistically significant
difference between the 2 groups was not observed (P>0.05).
ISQ showed that the ErhBMP-2-coated implants were more
effective for osseointegration. A higher ISQ value was recorded
in the control group immediately after surgery, even though it
was not statistically significant. In the control group, ISQ value
was slightly higher at 2 weeks, but it decreased gradually at 4
and 12 weeks. The experimental group showed a smaller ISQ
value at 2 weeks than immediately after surgery, while the
values gradually increased at 4 and 12 weeks. The difference
between the 2 groups was statistically significant at 2 and 12
weeks (P<0.05). Considering the difficulty in obtaining good
initial stability in rabbits due to poor bone quality, a higher ISQ
value at 12 weeks in the experimental group suggests that
ErhBMP-2 may be a positive factor for facilitating favorable
outcomes for osseointegration. 
Numerous articles have recently been published on the
significance of rhBMP-2 concentration. In addition to the
published papers, our study warrants further investigation using
ErhBMP-2-coated anodized implants to evaluate outcomes
when various concentrations of ErhBMP-2 are applied. Further
studies are also needed to find out the ideal healing period for
implant stability.
6. Conclusion
Implant stability was similar in both groups at 2 and 4 weeks,
whereas the experimental group showed a greater implant
stability at 12 weeks than the control group. Histometric analysis
revealed that ITBD was significantly higher with time in the
experimental group than in the control group. Although there
were some limitations in this study, a greater degree of
ossointegration was observed in the experimental group.
ErhBMP-2-coated anodized implants may be useful particularly
in cases where bone quality is poor or bone volume is insufficient.
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